Compare Ascendis Pharma A/S (ASND) vs Sezzle Inc (SEZL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Sezzle Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Sezzle Inc trades at $174.44 (market cap $6.03B). The key difference: Ascendis Pharma A/S is far larger — about 2.9× Sezzle Inc's market cap. Which is the better fit depends on your goals.
| ASND | SEZL | |
|---|---|---|
Market Cap | $17.74B | $6.03B |
Sector | Health | Technology |
52-Week High | $277.18 | $183.24 |
52-Week Low | $163.32 | $50.97 |
Enterprise Value | $18.11B | $6.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SEZL trades at $179.38, up 1.3% today, with a bullish technical signal and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock exhibits high profitability with a 30.83% net income margin and 91.95% ROE, though valuation multiples like a P/E of 42.78 suggest premium pricing. Recent news highlights product expansion and raised guidance, supporting positive sentiment.
Outlook remains favorable given robust growth and operational leverage, but risks include high valuation sensitivity and regulatory scrutiny. Analyst consensus is bullish with a $149.50 price target, though current price exceeds this, indicating potential near-term consolidation. Investment appeal hinges on sustained execution amid competitive fintech dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
